Article info
PDFMovement disorders
Original research
Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia
- Correspondence to Professor Hubert H Fernandez, Center for Neurological Restoration, Cleveland Clinic Foundation, Cleveland, OH 44195, USA; fernanh{at}ccf.org
Citation
Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia
Publication history
- Received October 30, 2018
- Revised May 21, 2019
- Accepted June 18, 2019
- First published July 10, 2019.
Online issue publication
November 14, 2019
Article Versions
- Previous version (10 July 2019).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.